Create your Personal Health Record and unlock support built around you

  • Treatments and trials you qualify for
  • Education for your stage of care
  • Financial support for your medications
  • Solutions to your side effects
Is Blood Cancer in the Genes? Understanding Inherited Risk in MPN & MDS image

Is Blood Cancer in the Genes? Understanding Inherited Risk in MPN & MDS

Sep 17, 2026
01:00PM - 02:00PM EDT
Online Event
Overview

Join the HealthTree Foundation for an insightful webinar exploring inherited risks and genetic predispositions in MPN and MDS. Led by hematologist Dr. Srinivas Tantravahi and Catherine Levy, a certified genetic counselor, this session breaks down how family genetics and germline mutations contribute to bone marrow malignancies. You will learn about the latest in genetic testing, what your results mean for your treatment, and actionable steps to protect your loved ones. Bring your questions for a live Q&A session designed to give you and your family clarity, confidence, and peace of mind.

Agenda
1:00 PM
Introductions
Dalton Bean

Dalton introduces the agenda of the event and featured speakers Srinavas Tantravahi, MBBS and Catherine Levy, CGC

1:05 PM
Presentation
Srinavas Tantravahi, MBBS and Catherine Levy, CGC

Our guest speakers talk about inherited risk for MPNs and MDS

1:35 PM
Questions & Answers
Audience

Bring your questions!

Speakers & Moderators
Healthtree contact Dalton Bean

Dalton Bean

Dalton joined HealthTree in 2024 as the MPNs and MDS Program Manager. He is passionate about helping patients gain a better understanding of their health and treatment and sees it as a way to help empower individuals and their families who are affected by these diseases. Prior to joining HealthTree Dalton earned a Master’s Degree in Oncological Sciences while studying various different blood cancers. When not interacting with patients he is an avid snowboarder and hiker.
Healthtree contact Srinvivas Tantravahi, MBBS, MRCP

Srinvivas Tantravahi, MBBS, MRCP

Dr. Srinivas Tantravahi is an Associate Professor specializing in Hematology and Hematologic Malignancies within the Division of Hematology at the Huntsman Cancer Institute, University of Utah. Board certified in Hematology and Medical Oncology, Dr. Tantravahi is an expert in the management of leukemias, myeloproliferative neoplasms, bone marrow failure, and genetic predisposition to related conditions. After completing his Internal Medicine residency and Hematology and Oncology fellowship training at the University of Utah School of Medicine, Dr. Tantravahi joined the University of Utah faculty in 2015. He actively engages in pioneering clinical trials, investigating innovative therapeutic strategies for myeloproliferative neoplasms, chronic myeloid leukemia, acute myeloid leukemia, and acute lymphoblastic leukemia. Dr. Tantravahi is a member of American Society of Hematology, Society of Hematologic Oncology, and American Society of Clinical Oncology. Dr. Tantravahi's clinical and research focus extends to the diagnosis and treatment of telomere biology disorders, with a particular emphasis on unraveling the genetic mechanisms underlying these disorders and various germline predispositions to bone marrow failure and leukemias.
Healthtree contact Catherine Levy, CGC

Catherine Levy, CGC

Cate Levy is a board-certified genetic counselor with a master’s degree in human genetics and genetic counseling from Keck Graduate Institute. She received her bachelor’s degree from the University of Colorado Boulder in neuroscience. Cate began working at Huntsman Cancer Institute in 2023 and specializes in hereditary predispositions to bone marrow failure as well as disorders of hemostasis and thrombosis. She participates in ongoing research at Huntsman Cancer Institute, with her research and clinical work having been published in peer-reviewed journals to help contribute to the understanding and management of rare cancer predisposition syndromes.